

Publication list

2026

Preventive efficacy of riamilovir in acute respiratory viral infections: an individual participant data pooled analysis of two prospective studies

Authors: Kozlov K.V., Maltsev O.V., Brianskaia-Kasyanenko K

Publication: Infectious Diseases: News, Opinions, Training. Journal named after Academician N.D. Yushchuk. 2026; 15 (2): 91–9

DOI: <https://doi.org/10.33029/2305-3496-2026-15-2-91-99>

Evaluation of the efficacy and safety of riamilovir for preventing acute respiratory viral infections in young adults in organized collectives.

Authors: Kozlov K.V.; Maltsev O.V.; Brianskaia-Kasianenko K.V.; Saulevich A.V.; Provotorov D.V.; Cheprakova V.A.; Lioznov D.A.; Komissarov A.B.; Lobzin Yu.V.; Zhdanov K.V.

Publication: Journal Infectology. 2026; 18(1): 26–35.

DOI: <https://doi.org/10.22625/2072-6732-2026-18-1-26-35>

Modern approaches to non-specific dengue control in Southeast Asia.

Authors: Kozlov K.V.; Soloviev A.I.; Maltsev O.V.; Brianskaia-Kasianenko K.V.; Peredelsky E.V.; Blyumkin D.B.; Solovieva P.A.; Novitsky A.A.; Luong Thi Mo.

Publication: Epidemiology and Infectious Diseases. Current Items. 2026; 16(1): 88–94.

DOI: <https://doi.org/10.18565/epidem.2026.16.1.88-94>

The possibility of using the drug riamilovir for the prevention of tick-borne encephalitis.

Authors: Tikhonova E.P.; Savchenko A.A.; Anisimova E.N.; Kalinina Yu.S.; Borisov A.G.

Publication: Infectious Diseases: News, Opinions, Training. 2026; 15(1): 55–63.

DOI: <https://doi.org/10.33029/2305-3496-2026-15-1-55-63>

Comparative evaluation of the efficacy of antiviral therapy agents in moderate COVID-19 with different drug administration timings.

Authors: Sabitov A.U.; Kuznetsov P.L.; Kuznetsova A.S.; Khamanova Yu.B.; Moskaleva Yu.N.

Publication: Infectious Diseases. 2026; 24(1): 29–36.

DOI: <https://doi.org/10.20953/1729-9225-2026-1-29-36>

2025

Atypical course of dengue fever with a symptom complex of acute hepatitis.

Authors: Pshenichnaya N.Yu.; Khoreva V.V.; Shipilov M.V.; Luzhetskaya A.A.

Publication: Epidemiology and Infectious Diseases. Current Items. 2025; 15(4): 16–21.

DOI: <https://doi.org/10.18565/epidem.2025.15.4>

Efficacy of antiviral therapy initiated at a later stage of acute respiratory viral infections: data from a comparative observational study.

Authors: Kozlov K.V.; Maltsev O.V.; Gorelov A.V.; Zhdanov K.V.; Brianskaia-Kasyanenko K.; Sukachev V.S.; Provotorov D.V.

Publication: Infectious Diseases: News, Opinions, Training. 2025; 14(3): 19–27.

DOI: <https://doi.org/10.33029/2305-3496-2025-14-3-19-27>

Experience in using antiviral drug riamilovir in a patient with epidemic parotitis.

Authors: Tikhonova E.P.; Kuzmina T.Yu.; Kalinina Yu.S.; Chernykh V.I.

Publication: Infektsionnye bolezni: novosti, mneniya, obucheniye. 2025; 14(2): 136–139.

DOI: <https://doi.org/10.33029/2305-3496-2025-14-2-136-139>

New approaches to comprehensive therapy of Dengue fever.

Authors: Maltsev O.V.; Kozlov K.V.; Dambaev I.S.; Brianskaya-Kasyanenko K.; Novitsky A.A.; Solovieva P.A.

Publication: Infectious Diseases. 2025; 23(2): 90–98.

DOI: <https://doi.org/10.20953/1729-9225-2025-2-90-98>

Evaluation of the Effectiveness of Riamilovir in Prevention of COVID-19: Mathematical Simulation Results.

Authors: Sigidaev Aleksey S.; Zotov Pavel B.; Duldin Vasiliy A.; Iva Irina I.; Kozlov Konstantin V.; Maltsev Oleg V.; Ivanova Vera V.; Bryanskaya-Kasyanenko Kristina.

Publication: Antibiotics and Chemotherapy. 2025; 70(1–2): 37–44.

DOI: <https://doi.org/10.37489/0235-2990-2025-70-1-2-37-44>

Prospects for Expanding the Possibilities of Etiotropic Therapy of Acute Respiratory Viral Infections in Primary School Children.

Authors: Zhdanov Konstantin V.; Lobzin Yuri V.; Sabitov Alebay U.; Esaulenko Elena V.; Sorokin Pavel V.

Publication: Antibiotics and Chemotherapy. 2025; 70(1–2): 29–36.

DOI: <https://doi.org/10.37489/0235-2990-2025-70-1-2-29-36>

A meta-analysis of randomized clinical trials of the effectiveness of Riamilovir in the etiotropic therapy of acute respiratory viral infections in patients of different age groups.

Authors: Gorelov A.V.; Lobzin Yu.V.; Zhdanov K.V.; Lioznov D.A.; Kozlov K.V.; Sabitov A.U.; Esaulenko E.V.; Sorokin P.V.

Publication: Infectious Diseases: News, Opinions, Training. 2025; 14(1): 16–26.

DOI: <https://doi.org/10.33029/2305-3496-2025-14-1-16-26>

Meta-analysis of randomized clinical trials on the efficacy of Riamilovir in the etiotropic treatment of acute respiratory viral infections in school-age children.

Authors: Gorelov A.V.; Zhdanov K.V.; Lobzin Yu.V.; Sabitov A.U.; Lioznov D.A.; Esaulenko E.V.; Sorokin P.V.

Publication: Infectious Diseases. 2025; 23(1): 73–84.

DOI: <https://doi.org/10.20953/1729-9225-2025-1-73-84>

The use of riamilovir as part of combination antiviral therapy in adult population.

Authors: Mokoyan Zhanna T.; Svistushkin Valeriy M.; Nikiforova Galina N.; Struve Andrey V.; Vtorova Yuliya A.

Publication: MEDITSINSKIY SOVET. 2025; 19(7): 46–51.

DOI: <https://doi.org/10.21518/ms2025-072>

2024

Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives.

Authors: Kozlov Konstantin V.; Maltsev Oleg V.; Kasyanenko Kristina V.; Sukachev Vitalii S.; Saulevich Andrei V.; Karyakin Sergey S.; Dubrovin Alexey D.; Smirnov Roman N.

Publication: Terapevticheskii Arkhiv. 2024; 96(11): 1035–1041.

DOI: <https://doi.org/10.26442/00403660.2024.11.203024>

Dynamics of Matrix Metalloproteinase-9 Levels in the Novel Coronavirus Infection COVID-19.

Authors: Sabitov Alebay U.; Khamanova Yulia B.; Moskaleva Yulia N.; Kamaev Evgeniy Yu.; Kuznetsov Pavel L.; Medvedeva Maria D.

Publication: Antibiotics and Chemotherapy. 2024; 69(7–8): 30–36.

DOI: <https://doi.org/10.37489/0235-2990-2024-69-7-8-30-36>

Comparative assessment of the clinical effectiveness of direct-acting antiviral drugs in outpatient patients with acute respiratory viral infections.

Authors: Kozlov Konstantin V.; Maltsev Oleg V.; Kasyanenko Kristina V.; Sukachev Vitalii S.; Lyashenko Yuri I.; Kosuhina Anastasia A.

Publication: Terapevticheskii Arkhiv. 2024; 96(8): 797–803.

DOI: <https://doi.org/10.26442/00403660.2024.08.202911>

Experience in the treatment of severe dengue fever with riamilovir.

Authors: Pshenichnaya N.Yu.; Luzhetskaya A.A.; Konnova Yu.A.; Tsvetkova N.A.; Lizinfeld I.A.; Zhdanov K.V.

Publication: Infectious Diseases. 2024; 22(2): 133–136.

DOI: <https://doi.org/10.20953/1729-9225-2024-2-133-136>

Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19.

Authors: Sabitov Alebai U.; Lioznov Dmitry A.; Zhdanov Konstantin V.; Tikhonova Elena P.; Esaulenko Elena V.; Kovtun Olga P.; Kuznetsov Pavel L.; Sorokin Pavel V.

Publication: Terapevticheskii Arkhiv. 2024; 96(5): 515–520.

DOI: <https://doi.org/10.26442/00403660.2024.05.202770>

Efficacy and safety of oral antiviral therapy medications in the treatment of moderate and severe cases of COVID-19. Results of a comparative retrospective observational study.

Authors: Sabitov A.U.; Tikhonova E.P.; Esaulenko E.V.; Kuznetsov P.L.; Sharova A.A.; Yelistratova T.A.; Kalinina Yu.S.; Andreeva I.V.; Basina V.V.; Oleinichenko E.V.; Edin A.S.

Publication: Antibiotics and Chemotherapy. 2024; 69(1–2): 37–43.

DOI: <https://doi.org/10.37489/0235-2990-2024-69-1-2-37-43>

Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of the drug riamilovir for the prevention of COVID-19.

Authors: Sabitov A.U.; Lioznov D.A.; Zhdanov K.V.; Tikhonova E.P.; Esaulenko E.V.; Sorokin P.V.

Publication: Terapevticheskii Arkhiv. 2024; 96(3): 229–234.

DOI: <https://doi.org/10.26442/00403660.2024.03.202652>

2023

Antiviral therapy for COVID-19.

Authors: Larchenko Yu.A.; Agapova O.Yu.; Mar'in G.G.; Vakhrushkina O.E.; Kukharensk M.V.; Nistor S.Yu.; Guseva T.F.; Medvedeva E.A.; Zykov K.A.

Publication: Russian Medical Inquiry. 2023; 7(11): 759–765.

DOI: <https://doi.org/10.32364/2587-6821-2023-7-11-8>

Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults.

Authors: Zhdanov K.V.; Maltsev O.V.; Kasyanenko K.V.; Kozlov K.V.; Sukachev V.S.; Lvov N.I.; Sharabkhanov V.V.; Litvinov A.A.

Publication: Terapevticheskii Arkhiv. 2023; 95(11): 930–936.

DOI: <https://doi.org/10.26442/00403660.2023.11.202471>

The experience in treatment of dengue fever using antiviral drug riamilovir in the Republic of Guinea (case report).

Authors: Maltsev O.V.; Kasyanenko K.V.; Zhdanov K.V.; Malyshev N.A.; Kolomoets E.V.; Konomou V.K.

Publication: *Terapevticheskii Arkhiv*. 2023; 95(1): 85–89.

DOI: <https://doi.org/10.26442/00403660.2023.01.202054>

The results of preclinical studies assessing the effect of riamilovir on the reproductive function and postnatal growth of offspring in laboratory animals.

Authors: Sabitov A.U.; Larionov L.P.; Dobrinskaya M.N.; Ledyankina O.V.; Osipenko A.V.; Valamina I.E.; Filippova E.V.; Fatikhov I.M.

Publication: *Antibiotics and Chemotherapy*. 2023; 68(5–6): 24–32.

DOI: <https://doi.org/10.37489/0235-2990-2023-68-5-6-24-32>

2022

A new approach to etiotropic therapy ARVI in children.

Authors: Sabitov A.U.; Kovtun O.P.; Esaulenko E.V.; Sorokin P.V.

Publication: *Terapevticheskii Arkhiv*. 2022; 94(11): 1295–1301.

DOI: <https://doi.org/10.26442/00403660.2022.11.201979>

Prospects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infection.

Authors: Maltsev O.V.; Kasyanenko K.V.; Kozlov K.V.; Zhdanov K.V.; Lapikov I.I.

Publication: *Terapevticheskii Arkhiv*. 2022; 94(10): 1171–1176.

DOI: <https://doi.org/10.26442/00403660.2022.10.201920>

Triazavirin—A Novel Effective Antiviral Drug.

Authors: Chupakhin O.N.; Rusinov V.L.; Varaksin M.V.; Ulomskiy E.N.; Savateev K.V.; Butorin I.I.; Du W.; Sun Z.; Charushin V.N.

Publication: *International Journal of Molecular Sciences*. 2022; 23: 14537.

DOI: <https://www.mdpi.com/1422-0067/23/23/14537>

The effect of etiotropic therapy on the formation of immune disorders in patients with COVID-19.

Authors: Tikhonova E.P.; Savchenko A.A.; Yelistratova T.A.; Kalinina Yu.S.; Kuzmina T.Yu.; Kasparov E.V.; Belenyuk V.D.; Sadovsky I.S.; Borisov A.G.

Publication: *Infectious Diseases: News, Opinions, Training*. 2022; 11(3): 61–68.

DOI: <https://doi.org/10.33029/2305-3496-2022-11-3-61-68>

2021

The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19.

Authors: Sabitov A.U.; Sorokin P.V.; Dashutina S.U.

Publication: Antibiotics and Chemotherapy. 2021; 66(1–2): 33–37.

DOI: <https://doi.org/10.37489/0235-2990-2021-66-1-2-33-37>

Comparative Effectiveness of Riamilovir and Umifenovir for Treating Influenza.

Authors: Popov A.F.; Markelova E.V.; Komarova I.A.; Beniova S.N.

Publication: Antibiotics and Chemotherapy. 2021; 66(3–4): 35–39.

DOI: <https://doi.org/10.37489/0235-2990-2021-66-3-4-35-39>

Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of “Multi-hit” Approach.

Authors: Zykov K.A.; Sinitsyn E.A.; Rvacheva A.V.; Bogatyreva A.O.; Zykova A.A.; Shapovalenko T.V.

Publication: Antibiotics and Chemotherapy. 2021; 66(3–4): 49–61.

DOI: <https://doi.org/10.37489/0235-2990-2021-66-3-4-49-61>

Meta-analysis of randomized controlled clinical trials of Riamilovir efficacy in the etiotropic therapy of acute respiratory viral infection.

Authors: Sabitov A.U.; Kovtun O.P.; Batskalevich N.A.; Maltsev O.V.; Zhdanov K.V.; Esaulenko E.V.; Tikhonova E.P.; Kalinina Yu.S.; Sorokin P.V.; Chepur S.V.; Stepanov A.V.

Publication: Antibiotics and Chemotherapy. 2021; 66(5–6): 48–57.

DOI: <https://doi.org/10.37489/0235-2990-2021-66-5-6-48-57>

Meta-analysis of Randomized Clinical Trials of Riamilovir Efficacy in Etiotropic Therapy of Influenza.

Authors: Sabitov A.U.; Kovtun O.P.; Batskalevich N.A.; Lvov N.I.; Maltsev O.V.; Zhdanov K.V.; Esaulenko E.V.; Tikhonova E.P.; Kalinina Yu.S.; Sorokin P.V.; Chepur S.V.; Stepanov A.V.

Publication: Antibiotics and Chemotherapy. 2021; 66(5–6): 58–71.

DOI: <https://doi.org/10.24411/0235-2990-2021-66-6-6-58-71>

Study of Riamilovir Activity Against SARS-CoV-2 Infection in Syrian Hamsters.

Authors: Chepur S.V.; Smirnova A.V.; Kirienko A.N.; Myasnikova I.A.; Kanevsky B.A.; Sorokin P.V.

Publication: Antibiotics and Chemotherapy. 2021; 66(7–8): 13–19.

DOI: <https://doi.org/10.37489/0235-2990-2021-66-7-8-13-19>

Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19.

Authors: Kasyanenko K.V.; Kozlov K.V.; Maltsev O.V.; Lapikov I.I.; Gordienko V.V.; Sharabhanov V.V.; Sorokin P.V.; Zhdanov K.V.

Publication: Terapevticheskii Arkhiv. 2021; 93(3): 290–294.

DOI: <https://doi.org/10.26442/00403660.2021.03.200719>

Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19).

Authors: Sabitov A.U.; Sorokin P.V.; Dashutina S.Yu.

Publication: Terapevticheskii Arkhiv. 2021; 93(4): 435–439.

DOI: <https://doi.org/10.26442/00403660.2021.04.200751>

Experience in organizing the work of doctor-nurse teams of joint detachments of the Russian Federation's Armed Forces in the Italian Republic under the supervision of medical epidemiologists.

Authors: Trishkin D.V.; Kuandykov M.G.; Azarov I.I.; Akimkin V.G.; Kuzin A.A.; Yumanov A.P.; Kolesnikov V.V.; Smirnov A.V.; Pshenichnaya N.Yu.; Degtyarev A.A.; Tatarenko A.Yu.; Filippov A.V.; Davidov M.M.; Spirichev A.N.; Semenov A.V.; Dmitrakovich D.V.

Publication: Epidemiology and Infectious Diseases. Current Items. 2021; (4): 96–102.

DOI: <https://doi.org/10.18565/epidem.2021.11.4.96-102>

2020

Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19.

Authors: Sabitov A.U.; Belousov V.V.; Edin A.S.; Oleinichenko E.V.; Gladunova E.P.; Tikhonova E.P.; Kuzmina T.Yu.; Kalinina Yu.S.; Sorokin P.V.

Publication: Antibiotics and Chemotherapy. 2020; 65(7–8): 27–30.

DOI: <https://doi.org/10.37489/0235-2990-2020-65-7-8-27-30>

Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection.

Authors: Kasyanenko K.V.; Maltsev O.V.; Kozlov K.V.; Lapikov I.I.; Lvov N.I.; Sukachev V.S.; Zhdanov K.V.; Sorokin P.V.; Ratnikova A.K.

Publication: Antibiotics and Chemotherapy. 2020; 65(11–12): 16–21.

DOI: <https://doi.org/10.37489/0235-2990-2020-65-11-12-16-21>

The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection.

Authors: Lioznov D.A.; Tokin I.I.; Zubkova T.G.; Sorokin P.V.

Publication: Therapeutic Archive. 2020; 92(12): 59–63.

DOI: <https://doi.org/10.26442/00403660.2020.12.200427>

Evaluation of the efficacy of antiviral treatment of influenza A (subtype H1N1) during 2017–2018 and 2018–2019 epidemic seasons.

Authors: Emelyanova A.N.; Tikhonova E.P.; Kuzmina T.Yu.; Emelyanov A.S.; Chuprova G.A.; Epifantseva N.V.; Klimovich K.I.; Radyukin N.O.; Radyukin E.O.; Yurchuk S.V.; Vitkovskii Yu.A.

Publication: Experimental and Clinical Pharmacology. 2020; 83(3): 23–27.

DOI: <https://doi.org/10.30906/0869-2092-2020-83-3-23-27>

The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol.

Authors: Wu Xiaoke; Yu Kaijiang; Wang Yongchen; Xu Wanhai; Ma Hongli; Hou Yan; Li Yue; Cai Benzhi; Zhu Liying; Zhang Min; Hu Xiaoli; Gao Jingshu; Wang Yu; Qin Huichao; Zhao Mingyan; Zhang Yong; Li Kang; Du Zhimin; Yang Baofeng.

Publication: Engineering (Beijing). 2020; 6(10): 1199–1204.

DOI: <https://doi.org/10.1016/j.eng.2020.06.011>

2019

The Possibilities of Etiotropic Therapy for Influenza and ARVI with Taking into Account the Period of Hospitalization and the Risk of Developing Secondary Complications.

Authors: Verevshchikov V.K.; Shemyakina E.K.; Sabitov A.U.; Khamanova Y.B.

Publication: Antibiotics and Chemotherapy. 2019; 64(3–4).

DOI: <https://doi.org/10.24411/0235-2990-2019-100012>

Nucleoside analogues for the treatment of influenza: history and experience.

Authors: Kasianenko K.V.; Lvov N.I.; Maltsev O.V.; Zhdanov K.V.

Publication: Journal Infectology. 2019; 11(3): 20–26.

DOI: <https://doi.org/10.22625/2072-6732-2019-11-3-20-26>

Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug.

Authors: Tokin I.I.; Zubkova T.G.; Drozdova Yu.V.; Lioznov D.A.

Publication: Infectious Diseases. 2019; 17(4): 13–17.

DOI: <https://doi.org/10.20953/1729-9225-2019-4-13-17>

2018

Comparative clinical and economic evaluation of two alternative antiviral therapy regimens for influenza patients.

Authors: Tokin I.I.; Tsvetkov V.V.; Golobokov G.S.

Publication: Journal Infectology. 2018; 10(2): 110–116.

DOI: <https://doi.org/10.22625/2072-6732-2018-10-2-110-116>

Potential for use of triazavirin in combination therapy for treating tick-borne viral encephalitis in adults.

Authors: Tikhonova E.P.; Kuzmina T.Yu.; Anisimova A.A.; Kalinina Yu.S.

Publication: Experimental and Clinical Pharmacology. 2018; 81(9): 21–25.

DOI: <https://doi.org/10.30906/0869-2092-2018-81-9-21-25>

Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections.

Authors: Tikhonova E.P.; Kuz'mina T.Yu.; Andronova N.V.; Tyushevskaya O.A.; Elistratova T.A.; Kuz'min A.E.

Publication: Kazan Medical Journal. 2018; 99(2).

DOI: <https://doi.org/10.17816/KMJ2018-215>

Application of a new domestic antiviral drug (triazavirin) in etiotropic treatment of influenza.

Authors: Ratnikova L.I.

Publication: Experimental and Clinical Pharmacology. 2018; 81(3): 24–28.

DOI: <https://doi.org/10.30906/0869-2092-2018-81-3-24-27>